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Amongst the highly diverse Escherichia coli population 1 , the ST131-O25b:H4 clonal complex 58 is of particular concern. Since its first description in 2008 in a limited number of countries, 59 this clone has spread worldwide and shown an uncommon ability to propagate in humans. 2, 3 60 Moreover, ST131-O25b:H4 E. coli strains have a high pathogenic potential, 4 they belong to 61 the B2 phylogroup where most extraintestinal-pathogenic E. coli are classified, 5 they express 62 a large number of virulence factors 6 and are lethal in a mouse model of sepsis. 7 Involved in 63 community as well as hospital-acquired infections, ST131-O25b:H4 isolates are responsible 64 for a wide range of pathologies, from common cystitis to life threatening meningitis. 2 Finally, 65 these clones are also particularly worrisome as they are associated with a high level of 66 resistance to betalactams (mainly via the production of CTX-M-15 ESBL but also 67 carbapenemase 8 ) and fluoroquinolones. 9, 10 More recently described, the worrying plasmid-68 mediated colistin resistance gene, mcr-1, has been found in an ST131 strain, highlighting the 69 propensity of this ST to carry antibiotic resistance genes. 11 To a lesser extent, O25b strains 70 may belong to another spreading antibiotic resistant clonal complex with a high 71 extraintestinal pathogenic potential, the ST69 ("clonal group A"). 12 72 The lack of new antibiotics and the worldwide continuous increase of the infections caused 73 by multidrug resistant bacterial pathogens have revived attention to phage therapy, 13 74 boosting the search for novel bacteriophages. Numerous experimental data have been 75 published demonstrating the proof of concept of this approach and clinical trials have been 76 reported or are ongoing (http://www.clinicaltrials.gov). 77 In this work, we characterized a novel virulent bacteriophage, LM33_P1, which only infects 78 E. coli O25b strains. The in vitro and in vivo efficacies of bacteriophage LM33_P1 are 79 reported, showing its value for therapeutic applications. Bacterial strains and bacteriophages, susceptibility testing 85 The bacterial strains used in this work belong to previously published collections: human 86 commensal and extraintestinal E. coli gathered in France during the 2010s (n=83), 14-16 87 Spanish extraintestinal E. coli (n=16), 6 North American clinical E. coli (n=14), 17 , commensal 88 and pathogenic E. coli from various parts of the world (Africa, America, Australia, Europa 89 (n=18), 18, 19 the ECOR collection (n=8) 20 as well as the unpublished ColoColi collection (n=144, 90 an ongoing French multicenter study collecting E. coli strains in the lower respiratory tract of 91 mechanically ventilated patients). The phylogroup and the ST belonging were determined as 92 described in. 21, 22 The O-type and the fimH allele were determined by PCR-based assays as 93 previously described 18, 23 and as reported in Supplementary Data -Procedures, respectively. 94 When needed, we confirmed the O25b phenotype using a monospecific O25 serum designed 95 for E. coli serotyping purpose (E. coli mono O25, Statens Serum Institut, Denmark). 96 All the strains were grown in lysogeny broth (LB) (Difco™: Bacto-Tryptone: 10: g/L,: Difco™: 97 Yeast extract Difco 5 g/L, NaCl 5 g/L). Their antibiotic susceptibility was determined using the 98 disk diffusion method following the EUCAST guidelines. 99 Some E. coli strains, used for lipopolysaccharide (LPS) assays or bacteriophage susceptibility 100 testing, are detailed below: 101 -LM33, LM36, AVC02 (ST131-O25b:H4) and AVC03 (O25b, non-ST131) are clinical 102 strains responsible for ventilator-associated pneumonia, 103 -536 (ST127-O6), LM02 (ST69-O17) and ECOR51 (ST73-O25a) have been used as a 104 source of their corresponding LPS, 105 -81009 WT (ST131-O25b:H4) and its isogenic rough derivative (a mutant strain 106 obtained by deleting the gene encoding for the O-antigen ligase) 24 were used to 107 prove the LPS-dependent interaction of LM33_P1. 108 The bacteriophages were isolated from sewage, using specific host. 25 The lysis kinetic was performed as detailed in Fig. S4 . Briefly, the growth of LM33 with and 147 without LM33_P1 was followed overtime by recording optical density at 600 nm every 15 148 minutes. The aggregation assays were performed using an O25 E. coli anti-serum (see above) 149 and observed under light microscope as detailed in Fig. S7 160 The primary experimental outcome was the decrease in bacterial load in relevant organs. 161 As LM33 was originally responsible for a ventilator-associated pneumonia in an ICU patient, 162 pneumonia was initiated by intranasal administration of 1x10 8 cfu of strain LM33 on 163 anesthetized mice (n=20) as previously described. 32 The septicemia model, essentially used 164 to study intrinsic extraintestinal virulence of E. coli isolates, 7 was carried out with 1x10 9 cfu 165 of the strain H1659 (ST131-O25b:H4), injected subcutaneously into the nape of the neck 166 (n=12 mice). We used this strain because of its virulence, previously investigated. 6 The non-167 lethal urinary tract infection model consists in a retrograde kidneys infection occurring after 168 an intra-urethral injection of 5x10 7 cfu of strain LM33 into the bladder (n=23 mice), as 169 previously described. 33 In every case, the organs were aseptically removed and mechanically 170 homogenized in cold PBS before counting bacterial and bacteriophage content. (pLM33) and the bacterial chromosome ( Table 1) . 197 We determined the host range of bacteriophage LM33_P1 on a panel of 283 E. coli strains 198 belonging to various O-types ( Fig. 1 and Data sheet 1 provided separately for O25 and O16 199 strains). One hundred and eighty-three (64%) of these strains were not O25b and none of 200 them was infected by LM33_P1, including twelve O25a strains and six ST131-O16 strains. 201 Among the remaining one hundred O25b strains (encompassing 83 ST131, 4 ST69, 10 ST95 202 and 3 other STs), 64 (64%) were infected by LM33_P1 with a median efficiency of plaquing of 203 0.46 [0.09-1.27] ( Fig. S1) . Interestingly, LM33_P1 was found to be more efficient on STs 204 associated with high antibiotic resistance (ST131 and ST69, n=87) where 61 of these strains 205 (70%) were lysed whereas its efficacy was weak on STs associated with low antibiotic 206 resistance (ST95 and others, n=13) where only 3 of these strains (23%) were susceptible 207 ( Fig. 1) . Finally, we did not find a correlation between the susceptibility to bacteriophage 208 LM33_P1 and the fimH allele H30, which is strongly associated with fluoroquinolone 209 resistance among ST131 strains. 34 Indeed, considering the two more frequent fimH alleles in 210 our O25b strains (H22 and H30, n=83), the proportion of susceptible strains to LM33_P1 was 211 72% (21 out of 29) and 66% (36 out of 54) in the strains displaying respectively the H22 or (Table S1) : three coliphages called PE3-220 1, K1F, 35 EcoDS1 (with:94%:identity:on:≥ 88% of its length for all of them) and bacteriophage 221 Dev2 infecting Cronobacter turicensis (with 83% identity on 85% of its length). 36 The 222 alignment of these related bacteriophages with LM33_P1 revealed a similar spatial genome 223 organization and confirmed the high homology between them (Fig. 2) . Strikingly, the 5': Bacteriophage LM33_P1 is highly efficient and rapid in vitro. The adsorption of LM33_P1 238 bacteriophage on its host is:fast:with:≥:90%:of:the:viral:population:attached:to:cells:after:35: 239 minutes with an adsorption constant of 1.2x10 -8 mL/min ( Fig. S3-A) . Newly produced virions 240 are detected within the bacteria by 7 minutes post-infection (eclipse period) while host lysis 241 occurs in 9 minutes (latent period) with a burst size of 317 (95% confidence interval: 289-242 345) ( Fig. S3-B) . 243 In liquid medium, when LM33_P1 was mixed with its host, the absorbance value of LM33 244 cells started to decline (a sign of lysis) within 15 minutes at a multiplicity of infection (MOI) 245 of 1. With much fewer bacteriophages (MOI of 10 -6 ) lysis still occurred within 60 minutes 246 ( Fig. S4) . On solid medium, LM33_P1 forms clear and large plaques, whose diameter 247 increases rapidly overtime with a visible halo around clear areas. This halo suggests the 248 presence of a diffusible enzyme that most likely carries a depolymerase activity 40 (Fig. S5) .
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Bacteriophage LM33_P1 specifically binds to O25b LPS O-antigen. The host range of 251 bacteriophage LM33_P1 strongly suggested that the O-chain of LPS could be involved in its 252 specificity. Using LPS competition assays we observed that purified LPS from strain LM33 253 was able to inhibit the interaction between bacteriophage LM33_P1 and strain LM33 as well 254 as other O25b strains. 255 First, we demonstrated that purified LPS reduced the number of plaque-forming units when 256 mixed with bacteriophages before application on a bacterial layer (mean reduction of 1.0 257 ±0.23 Log10 from 15 assays with five different O25b strains, Fig. S6-A) . Together with the 258 reduction of the number of plaques, we observed a reduction of the plaque diameters, 259 suggesting that the LPS molecules prevented newly released bacteriophages from infecting 260 the surrounding hosts (Fig. 3) . These observations are specific of the interaction of 261 bacteriophage LM33_P1 with O25b strains since: i) an O25b LPS extract from strain LM33 262 was not able to affect the interaction of other bacteriophages targeting non O25b strains 263 and ii) an LPS extract from non O25b strains (O25a, O6 and O17) was unable to alter the 264 interaction between bacteriophage LM33_P1 and strain LM33 (Table S2) . 265 Second, an LPS extract from O25b strain (LM33) also reduced the infectivity of 266 bacteriophage LM33_P1 in liquid medium in a dose dependent manner ( Fig. S6-B) , whereas 267 LPS extracts from O6 and O25a strains had no effect. 268 Third, using an O-type specific antibody to aggregate O25 strains for serotyping, we found 269 that bacteriophage LM33_P1 prevented the aggregation of strain LM33 (Fig. S7) . 270 Fourth, using E. coli O25b 81009 and its isogenic rough derivative (an LPS deficient strain 271 obtained by deleting the gene encoding for the O-antigen ligase) 24 The adsorption of bacteriophage LM33_P1 is most likely hindered by capsule production. 277 The production of exopolysaccharides is a well-known bacteriophage resistance mechanism 278 and might be involved in the non-adsorption of bacteriophage LM33_P1 observed in five 279 randomly chosen LM33_P1 resistant strains (81009 WT, JJ1886, S242, B-1, C-1). Since, in 280 some cases (type II capsule), the synthesis of exopolysaccharides is temperature dependent, 281 we investigated the susceptibility of LM33_P1 on all the O25b resistant strains (n=36) at 282 20°C. We observed that nine of them (25%) became susceptible at this temperature (see 283 Data sheet 1), supporting this hypothesis. 284 285 Bacteriophage LM33_P1 efficiently infects its host in vivo. As bacteriophage LM33_P1 286 exhibited impressive in vitro characteristics, we investigated its in vivo activity in three 287 different animal infection models relevant to ST131 clinical epidemiology: pneumonia, 288 septicemia and urinary tract infection ( Fig. 4-6 ). Since strain LM33 was isolated from a 289 patient with pneumonia, we first attempted to trigger pneumonia in mice. Using an 290 inoculum 50 times higher than previously reported in such model 32 cfu/g, intranasally LM33_P1-treated: 2.7x10 4 cfu/g, intraperitoneally LM33_P1-treated: 299 3.3x10 4 cfu/g, p <0.01, Fig. 4) . Interestingly, the number of bacteriophages in the lung tissue 300 was similar between the intranasally and intraperitoneally-treated mice despite the fact that 301 the latter had received a 10 times higher dose (Fig. 4) . 302 Then, we tested bacteriophage LM33_P1 in a murine model of septicemia previously 303 reported 6, 7 using the H1659 ST131-O25b:H4 strain 6 (strain LM33 was not lethal in this 304 model), on which LM33_P1 is as efficient as on strain LM33 (EOP = 1). Following a 305 subcutaneous inoculation of 1x10 9 cfu, septic metastases were rapidly observed in several 306 organs (the first deaths occurred in less than 24 hours). Intraperitoneal administrations of 307 bacteriophage LM33_P1 (MOI 60, a single dose 2 hours post-infection or two doses 2 hours 308 and 12 hours post-infection) were not sufficient to prevent the death of the animals. 309 However, in the subset of the animals that died within the same time interval (between 24 310 and 30 hours), the bacteria and bacteriophage content was analyzed in the liver, the spleen 311 and the lung-heart homogenates (Fig. 5) . In these organs, the number of bacteria was 312 reduced compared to the control group (untreated infected animals). A two doses regimen 313 appeared to be more efficient than a single one, enabling to reach a significant reduction of 314 approximately 1.4 Log10 (the median bacterial count decreases from 8.5x10 6 to 2.9x10 5 in 315 the heart-lungs, from 7.7x10 5 to 3.2x10 4 in the liver and from 3.5x10 5 to 1.4x10 4 cfu/g in the 316 spleen). The bacteriophage counts were in the same order of magnitude in all the organs, 317 but were significantly higher when two doses had been administered (2.0x10 10 versus 318 4.0x10 9 pfu/g, p <0.01). In addition, the amount of bacteriophages was 3 to 6 Log10 higher 319 than the amount of bacteria in each mouse for all the organs. All these observations 320 revealed that bacteriophage LM33_P1 was able to infect and multiply in vivo in strain H1659. 321 Finally, as E. coli is a major pathogen in UTIs, we assessed the efficacy of bacteriophage 322 LM33_P1 in a murine UTI model (Fig. 6) . Twenty-four hours following intra-urethral injection 323 of 5.10 7 cfu of strain LM33, the mice received a single bacteriophage treatment 324 intraperitoneally (MOI of 200). Forty-eight hours post-infection, a 2 Log10 reduction of 325 bacterial load was observed in the kidneys in the treated group compared to control group 326 (1.5x10 5 versus 8.8x10 2 cfu/g, p <0.001). 327 Altogether these data firmly show the ability of bacteriophage LM33_P1 to infect O25b 328 strains in vivo. Our investigations led us to estimate that the global host coverage of bacteriophage 355 LM33_P1 on O25b strains is 64%. We consider that this coverage is reliable as we first 356 avoided sampling bias by screening a large collection obtained from different sources with 357 many serotypes. Second, we assessed strain susceptibility in a rigorous way using EOP 358 determination that excludes atypical results and false positives such as those obtained with 359 lysis from without. 44, 45 On the other hand, one limitation of our study is the origin of the 360 strains we tested: as most of them originate from European countries (76%), further studies 361 will be required to assess whether coverage of LM33_P1 is higher, equal or lower if 362 submitted to strains originating from Asian, Indian, African or American countries. 363 Finally, compared to the data available in literature, we found that LM33_P1 is the quickest 364 T7-like bacteriophage ever reported, lysing its host within 10 minutes while T7 takes 13 to 16 365 minutes. 46, 47 Part of this success is due to its absorption constant (1.2x10 -8 mL/min) which 366 was found to be 10 times higher than that of most bacteriophages 48-51 and its burst size 367 which is also in the top half of the values usually observed. 52
368
To prevent phage adsorption, bacteria can mask phage receptors by the production of 369 extracellular exopolysaccharides (capsules), which can also help bacteria to escape 370 recognition by immune cells. 53, 54 We found that 25% of the strains reversed their phenotype 371 towards bacteriophage LM33_P1 from resistant to susceptible, when grown and tested at 372 20°C, a temperature known to turn off type II capsule production. 55 Therefore, the 373 bacteriophage LM33_P1 coverage increased to 80% among all the ST131-O25b:H4 strains 374 and to 73% among all the O25b strains tested. It was also previously shown that 375 bacteriophages can defeat such an exopolysaccharide shield by using tail fibers that possess 376 depolymerase activities. 56 We can reasonably assume that the discovery of new plates. An LPS extract from strain LM33 was mixed with bacteriophage LM33_P1 (left) or 609 536_P1 (right) at two different concentrations (10 5 and 10 4 pfu/mL) and assayed on two agar 610 plates overlaid with an O25b strain (AVC02) or an O6 strain (536) as control. Enlargements of 611 these two plates are shown to facilitate the observation. Table S2 Data obtained during plaque test inhibition assays with different LPS extracts and randomly chosen couples of viruses-bacteria. (+)/(-): presence/absence of an inhibitory effect of LPS extract, -: not tested. a described in reference 31 in the manuscript, b bacteriophages isolated using ventilator-associated pneumonia (VAP) strains (423, 416) and active on others VAP strains (H17, LM49), c bacteriophage isolated using an adherent-invasive E. coli (LF82) and active on VAP strain RY09.
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Figure S1
Distribution of the efficiency of plaquing values of bacteriophage LM33_P1. Dots represent individual values for each of the 64 strains tested whereas median (0.46) and 25th-75th percentiles [0.09-1.27] are indicated by lines. Y-axis is in Log scale.
Figure S2
Predicted tertiary structure of the the C-terminal part of bacteriophage LM33_P1 tail fiber using Phyre², compared to its closest homolog (Erwinia carotovora endopolygalacturonase).
Figure S3
A. Adsorption of bacteriophage LM33_P1 on its host LM33. Strain LM33 grown in LB at 37 °C with shaking (100 rpm) was mixed with bacteriophage LM33_P1 at a MOI of 10 -4 and aliquots were taken at the indicated time points. Dots represent the mean of 3 independent experiments with the standard deviation.
B. Bacteriophage LM33_P1 growth parameters. Bacteriophage LM33_P1 was mixed with strain LM33 (MOI 10 -1 ) at 37 °C with shaking. At the indicated time points, samples were analyzed in absence (grey lines) or in presence (black lines) of chloroform. The continuous lines represent the experimental measurements (mean of 3 independent experiments with standard error) while the dashed lines are the nonlinear regression obtained from these points.
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Figure S4
Lysis kinetics of strain LM33 by bacteriophage LM33_P1 at different multiplicity of infection. The panel A displays the first 22 hours of kinetic and the panel B displays a magnification of the first 2 hours. The lysis kinetics of the strain LM33 were performed as described previously (Maura et al., Environ Microbiol, 2012; 14(8):1844 -1854 in LB, at 37°C and with various multiplicity of infection (MOI). Optical density (600 nm) was followed over time and recorded each 15 minutes on a Glomax plate reader (Promega, Madison, USA). Strain LM33 without LM33_P1 was used as a control. All the conditions were performed in triplicates and the experiment was repeated three times independently (only one representative experiment is shown). For readability purpose, only mean of triplicates are displayed without the corresponding error bars.
Figure S5
A. The size of the plaques made by bacteriophage LM33_P1 increases rapidly over time.
LM33_P1 plaque-forming units on strain LM33 as visualized on LB-agar plate after 2 hours of incubation at 37 °C (left picture) and after 6 hours of infection (right picture).
B. A large halo surrounds plaques and area of lysis made by bacteriophage LM33_P1.
Three drops of 10 µL of LM33_P1 (5x10 3 pfu/mL) have been dropped off on a bacterial host layer and incubated at 37 °C for 21 (left) and 36 hours (right). A halo is clearly visible at 36 hours, surrounding the area of lysis.
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Figure S6
A: An O25b LPS extract inhibits interactions between bacteriophage LM33_P1 and O25b strains. Variations of bacteriophage titers from 15 individual plaque tests in presence or absence of O25b LPS extract are shown. For each individual assay, the same starting bacteriophage solution was titrated in triplicate, without and with LPS extract obtained from strain LM33. Each dot represents therefore the mean titer of the 3 replicates. Four O25b strains and different concentrations of LM33_P1 have been tested (see methods). B: O25b LPS extract inhibits bacteriophage LM33_P1 activity in liquid medium. The growth of strain LM33 in liquid broth was recorded every 15 minutes using optical density (OD600nm) in absence (red curve) or in presence of bacteriophage LM33_P1 (MOI of 10 -6 ) without (green) or with undiluted (black), 2-fold diluted (dark blue), 4-fold diluted (light blue) O25b LPS extract.
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Figure S7
Bacteriophage LM33_P1 prevents O25 antibody-mediated aggregation of strain LM33. A commercially available specific O25 E. coli anti-serum, sold to perform O-antigen serotyping, was obtained from the Statens Serum Institut (Copenhagen, Denmark). The tests were performed using old liquid cultures of strain LM33 in stationary phase in LB (in order to slow down and delay bacterial lysis). Four conditions were tested, with the following mixes: I-LM33 (5 µL) + Saline (NaCl 0.9%, 5 µL) + TN buffer (2 µL), II-LM33 (5 µL) + O25Ab (5 µL, in NaCl 0.9%) + TN (2 µL), III-LM33 (5 µL) pre-incubated 10 min at 20 °C with LM33_P1 (in TN, 2 µL, MOI of 10) + O25Ab (5 µL), IV-LM33 (5 µL) pre-incubated 10 min at 20 °C with LM33_P1 (in TN, 2 µL, MOI of 10) + Saline (5 µL). Following the incubation at 37 °C during 30 min, a drop (5 µL) of each condition was put on a glass slide and covered with a cover slip for direct examination under a phase contrast microscope. The upper line shows original pictures as obtained with a 40x magnification and the lower line represents a binary black and white transformation of the above pictures generated by ImageJ software (rsb.info.nih.gov/ij/).
Allele-specific PCR amplification for the identification of the fimH alleles 22, 30 and 41
The primers for the fimH allele-specific PCR and the length of the PCR products were as follows:
fimH22.f, fimH22.r, 234 bp; fimH30.f, fimH30.r, 354, bp; fimH41.f, fimH41.r, 431, bp. PCR reactions were carried out in a 20-µl volume containing 4 µl of 5X buffer (supplied with Taq polymerase), 10 pmol of each primer, 200 µM each dNTP, 2 U of Taq polymerase (Promega, Charbonnières-les-Bains, France), and 3 µl of bacterial lysate or 2 µl of DNA. PCR was performed with an Eppendorf Mastercycler with MicroAm tubes in the following conditions: denaturation 4 min at 94° C, 30 cycles of 5 sec at 94° C and 10 sec at 65°C, and a final extension step of 5 min at 72° C.
PCR products were loaded on 2% agarose gel with SYBR® Safe DNA gel stain (Invitrogen, Cergy-Pontoise, France). Following electrophoresis, gels were photographed under UV light.
The method was validated on a panel of E. coli strains from which the fimH sequence was available, i.e. 7, 19 and 47 strains exhibiting the fimH allele H22, H30 and H41, respectively, as well as 67 strains exhibiting none of these alleles (Ochman H, Selander RK. J Bacteriol. 1984 Feb; 157 (2) 
Bacteriophage susceptibility testing
For bacteriophage susceptibility testing, we used the double spot test technique as screening method and EOP calculation for all susceptible strains. The double spot test consisted in dropping off 10 µL of a growing liquid culture of the bacterial strain (OD 600nm 0.5) on an agar plate. After drying, 1 µL of the bacteriophage solution (LM33_P1, 10 7 pfu/mL) was added on one half of the bacterial drop. The plate was then incubated at 37°C during 4-8 hours before reading. A susceptible strain was identified by the presence of a crescentshaped lysis area on the bacterial drop or the visualization of individualized plaques. Efficiency of plaquing (EOP) was determined for all susceptible strains by titrating the solution of LM33_P1 on both its host (LM33) and the evaluated strain. EOP was calculated as the ratio of the number of plaques formed by the bacteriophage on the non-host strain to the number of plaques formed on its host, using the same bacteriophage solution. Only the strains for which individualized plaques were observed were considered as susceptible strains. For strain 81009 WT and its rough derivative mutant, tests were performed at 20 °C to turn-off type II capsule expression.
Characterization of bacteriophage LM33_P1
The adsorption assay and the one-step growth experiment were performed in triplicate, using Lysogeny Broth (Difco™,Bacto-Tryptone,10,g/L,Difco™,Yeast,extract,Difco,5,g/L,NaCl,5, g/L), under constant shaking (100 rpm) at 37°C, as described by Hyman and Abedon (Practical methods for determining phage growth parameters, Methods Mol Biol 501: 2009 ). A correlation curve was extrapolated from raw data using nonlinear regressions (GraphPad Prism 5.0, GraphPad software, California): a dose-response model was used for the one step growth experiment (Y=Bottom + (Top-Bottom)/(1+10^((LogEC50-X)*HillSlope)) with Y=log(pfu/infected cell) and X=time) and an exponential model with one phase decay for adsorption experiment (Y=(Y0 -Plateau)*exp(-K*X) + Plateau with Y=free phages(%), X=time). The growth parameters (eclipse and latent period, burst size) were then derived from these regressions. The adsorption constant was calculated as -p/N where p is the slope of the straight line obtained after a natural logarithm transform and N the concentration of bacteria at the beginning of the adsorption assay.
Sequencing of the strain LM33 and bacteriophage LM33_P1
The sequencing of bacteriophage LM33_P1 and strain LM33 was performed using Illumina sequencing technology (Illumina Inc., San Diego, CA). The LM33_P1 DNA was extracted from a purified bacteriophage solution, using DNase and RNase pretreatments followed by a phenol-chloroform extraction as described by Pickard (Pickard DJ, 2009, Preparation of bacteriophage lysates and pure DNA. Methods Mol Biol). The LM33 genomic DNA was extracted using a MaxWell Tissue DNA Purification kit (Promega, Madison, WI). Genomes annotation was performed by the MicroScope plateform for strain LM33 (Vallenet D, 2013, MicroScope: an integrated microbial resource for the curation and comparative analysis of genomic and metabolic data. Nucleic Acids Res) and with the RAST server for bacteriophage LM33_P1 (Aziz RK, 2008 , The RAST Server: rapid annotations using subsystems technology. BMC Genomics), followed by manual curation.
Murine experimental infections models
The animals were housed in authorized animal facilities in accordance with French and European regulations on the care and protection of laboratory animals. The protocols were approved of by the veterinary staff of the Institut Pasteur and INSERM animal facilities, as well as the National Ethics Committee regulating animal experimentation. The animals were housed in a SPF animal facility rated biosafety level 3 (Institut Pasteur) or 2 (INSERM). Food and drink were provided ad libitum. The mice were housed in separate ventilated cages corresponding to each group (control or phage-treated) and were visited at least twice daily to monitor health status. A daily weighing was performed and the mice were euthanized if weight loss greater than 20%, a limit that had never been reached here. The control group was always handled first (before the phage-treated group) to avoid phage contamination of the control group. The period of time between the infection and the treatment (phage or mock) was recorded and was identical between each group. For each infection model, the results provided are the sum of two or three independent experiments.
The bacteriophage solutions administered in the animal experiments were obtained from purified stock (as described in Material and Methods) and were submitted to an additional purification procedure to reduce endotoxin level using an affinity chromatography-based endotoxin removal kit (EndoTrap blue, Hyglos, Germany).
Pneumonia was initiated by intranasal administration of 1x10 8 cfu of strain LM33 on 20 anesthetized eight-week-old 25 g BALB/cJRj male mice (Janvier, Le Genest Saint Isle, France). The mice were treated using bacteriophage LM33_P1 four hours post-infection (n=12), either by using the intranasal route (multiplicity of infection of 50, i.e. a ratio of viruses to bacteria equal to 50) or the intraperitoneal route (MOI of 500). Control mice (n=8) received accordingly an intranasal or intraperitoneal identical volume of PBS (phosphate-buffered saline). The lungs were collected 17 hours post-infection on euthanized animals. An intraperitoneal administration, of, 1.25, μg, (50, μg/kg), of, buprenorphine, (Buprecare, ;ST, Farma, Oudewater, The Netherlands) was systematically performed on all the mice at 8 hours post infection to limit the pain and the dyspnea.
The septicemia model, as previously described, is essentially used to study the intrinsic extraintestinal virulence of E. coli isolates. Twelve four-week-old 17 g OF1 female mice (Janvier, Le Genest Saint Isle, France) were injected subcutaneously into the nape of the neck with 1x10 9 cfu of strain H1659 (ST131-O25b:H4). Because of the high inoculum used, we tested both a single and a double dose of bacteriophages: the single dose (MOI 60) was administered by an intraperitoneal injection 2 hours post-infection (n=4) while the double dose consisted in an injection (MOI 60) administered 2 and 12 hours post-infection (n=4). Control mice (n=4) received an identical volume of PBS. Organs targeted by septic metastasis (heart-lung, spleen and liver) were collected on the animals that died between 24 to 30 hours post-infection.
The urinary tract infection model consists in a retrograde kidneys infection occurring after an intra-urethral injection of 5x10 7 cfu of strain LM33 in the bladder (23 mice). Twenty-four hours after the infection, 8-week-old 17 g CBA/j female mice (Charles River, Chatillon-sur-Chalaronne, France) were treated intraperitoneally with LM33_P1 (MOI of 200, n=10) while control mice (n=13) received an identical volume of PBS. The kidneys were collected 48 hours post-infection.
The euthanasia of animals was performed by asphyxiation with rising concentration of CO 2 . In every case, the organs were mechanically homogenized in cold PBS using a gentleMACS Octo Dissociator (Milteny Biotec, Bergisch Gladbach, Germany) before being serially diluted and spread on Drigalski agar plates containing appropriate antibiotic to numerate colony, in triplicate. The bacteriophage count was performed in triplicate on supernatant after centrifugation of the homogenates according to routine methods.
